Research ArticleClinical Investigation
Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
Matthias D’Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte and Marleen Keyaerts
Journal of Nuclear Medicine August 2021, 62 (8) 1097-1105; DOI: https://doi.org/10.2967/jnumed.120.255679
Matthias D’Huyvetter
1Precirix NV/SA, Brussels, Belgium;
2In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium;
Jens De Vos
1Precirix NV/SA, Brussels, Belgium;
Vicky Caveliers
2In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium;
3Nuclear Medicine Department, UZ Brussel, Brussels, Belgium;
Ilse Vaneycken
3Nuclear Medicine Department, UZ Brussel, Brussels, Belgium;
Johannes Heemskerk
3Nuclear Medicine Department, UZ Brussel, Brussels, Belgium;
Francois P. Duhoux
4Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium;
Christel Fontaine
5Department of Medical Oncology, UZ Brussel, Brussels, Belgium;
Marian Vanhoeij
6Department of Oncological Surgery, UZ Brussel, Brussels, Belgium;
Albert D. Windhorst
7Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;
Frank van der Aa
7Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;
N. Harry Hendrikse
7Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;
Jos L.E. Eersels
1Precirix NV/SA, Brussels, Belgium;
2In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium;
Hendrik Everaert
3Nuclear Medicine Department, UZ Brussel, Brussels, Belgium;
Pieterjan Gykiere
3Nuclear Medicine Department, UZ Brussel, Brussels, Belgium;
Nick Devoogdt
1Precirix NV/SA, Brussels, Belgium;
2In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium;
Geert Raes
1Precirix NV/SA, Brussels, Belgium;
8Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; and
9Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium
Tony Lahoutte
Marleen Keyaerts
2In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium;
3Nuclear Medicine Department, UZ Brussel, Brussels, Belgium;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue 8
August 1, 2021
Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
Matthias D’Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte, Marleen Keyaerts
Journal of Nuclear Medicine Aug 2021, 62 (8) 1097-1105; DOI: 10.2967/jnumed.120.255679
Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
Matthias D’Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte, Marleen Keyaerts
Journal of Nuclear Medicine Aug 2021, 62 (8) 1097-1105; DOI: 10.2967/jnumed.120.255679